Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Motley Fool, Financial Times and Barron's. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Quick answers
Why is "Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter result" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction The Motley Fool · 4h ago
- Pfizer predicts higher profits as new drugs offset falling sales of Covid products Financial Times · 4h ago
- Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act Barron's · 4h ago
Topics
Related trends
Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act
Pfizer reports a Q3 earnings beat and raises its full-year outlook as it pivots toward cancer and weight-loss treatments in a post-pandemic strategy.
Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
Pfizer has raised its full-year outlook and appointed a new chief financial officer following strong third-quarter results.
Cancer Vaccines Are the N.I.H.’s Next ‘Big Bet’
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
What you need to know about this year’s fall vaccines
Health authorities and medical groups are updating guidance for the 2026 fall respiratory vaccine season, including new cost structures in Australia.
The updated COVID-19 vaccines have just been approved. Here’s what you can expect.
The US FDA has approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine as updated shots become available to the public.